European Commission Approves Astellas' Xtandi For Recurrent Early Prostate Cancer Treatment
24/4 02:57
(RTTNews) - Astellas Pharma Inc. (ALPMY) said that the European Commission has approved a label extension for Xtandi or enzalutamide as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent non-metastat...